跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HYRIMOZ - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
HYRIMOZ
Authorized
STANDARD
HYRIMOZ
Sandoz Canada, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
d6879b52e0e76615
Company
Sandoz Canada, Inc.
Type
Standard
Approval Details
Approval Id
d6879b52e0e76615
Drug Approval Canada Name
HYRIMOZ
Product Name
HYRIMOZ
Status
Marketed
Status Date
2024-04-05
Original Market Date
2024-04-05
Din
02542315
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
90:24.16.92
Atc Original
L04AB04 ADALIMUMAB
Atc Name
l 04 ab 04
Aig Number
0150364002
Company Name
Sandoz Canada, Inc.
Company Address
4600 Rue Armand-Frappier, Saint-Hubert, Quebec, Canada, J3Z 1G5
Company Detail Path
/organization/sandoz-canada-inc
Company Information
Pharmaceutical Company Name
Sandoz Canada, Inc.
Country Name
Canada
Website
http://www.sandoz.ca
Active Ingredients
ADALIMUMAB
20 MG / 0.2 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
d6879b52e0e76615
Type
Standard
Back to Health Canada Approvals